ARTICLE | Clinical News
GSK2586881: Phase IIa started
January 2, 2012 8:00 AM UTC
GlaxoSmithKline began a U.S. and Canadian Phase IIa trial to evaluate GSK2586881 in ALS patients. GSK has exclusive, worldwide rights to develop and commercialize the compound from Apeiron (see BioCen...